Insider · CIK 0001264949

ZANTE GREG

Reports to the SEC for 2 companies · SAN DIEGO, CA

sec.gov

Transactions

Companies

Filings

CIK

0001264949

Forms 4 and 5

Insider transactions

50 trades

Date	Company	Role	Code	Shares	Price	Value	Shares after
2026-07-29	VKTXViking Therapeutics, Inc.S Sale	Chief Financial Officer	SSale	−21.2K sh	$33.47	−$710K	212,204
2026-07-28	VKTXViking Therapeutics, Inc.A Award	Chief Financial Officer	AAward	+31.7K sh	—	—	233,421
2026-01-05	VKTXViking Therapeutics, Inc.S Sale	Chief Financial Officer	SSale	−32K sh	$32.30	−$1.03M	215,571
2026-01-05	VKTXViking Therapeutics, Inc.S Sale	Chief Financial Officer	SSale	−13.9K sh	$33.38	−$464K	201,671
2026-01-05	VKTXViking Therapeutics, Inc.S Sale	Chief Financial Officer	SSale	−10.3K sh	$34.24	−$353K	191,371
2026-01-05	VKTXViking Therapeutics, Inc.S Sale	Chief Financial Officer	SSale	−1,500 sh	$32.09	−$48.1K	189,891
2026-01-02	VKTXViking Therapeutics, Inc.A Award	Chief Financial Officer	AAward	+41K sh	—	—	215,483
2026-01-02	VKTXViking Therapeutics, Inc.A Award	Chief Financial Officer	AAward	+32K sh	—	—	247,532
2026-01-02	VKTXViking Therapeutics, Inc. · Stock Option (Right to Buy)A Award	Chief Financial Officer	AAward	+91K sh	—	—	91,000
2025-10-28	VKTXViking Therapeutics, Inc.S Sale	Chief Financial Officer	SSale	−6,185 sh	$35.00	−$216K	173,592
2025-10-27	VKTXViking Therapeutics, Inc.A Award	Chief Financial Officer	AAward	+11.1K sh	—	—	179,777
2025-07-03	VKTXViking Therapeutics, Inc.S Sale	Chief Financial Officer	SSale	−4,266 sh	$27.76	−$118K	168,660
2025-07-02	VKTXViking Therapeutics, Inc.A Award	Chief Financial Officer	AAward	+7,667 sh	—	—	172,926
2025-01-06	VKTXViking Therapeutics, Inc.S Sale	Chief Financial Officer	SSale	−45.6K sh	$42.69	−$1.95M	169,959
2025-01-06	VKTXViking Therapeutics, Inc.S Sale	Chief Financial Officer	SSale	−4,700 sh	$43.32	−$204K	165,259
2025-01-03	VKTXViking Therapeutics, Inc.A Award	Chief Financial Officer	AAward	+44.5K sh	—	—	193,901
2025-01-03	VKTXViking Therapeutics, Inc.A Award	Chief Financial Officer	AAward	+21.7K sh	—	—	215,568
2025-01-03	VKTXViking Therapeutics, Inc. · Stock Option (Right to Buy)A Award	Chief Financial Officer	AAward	+37.2K sh	—	—	37,200
2024-10-28	VKTXViking Therapeutics, Inc.M Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	+12.8K sh	$7.77	+$99.1K	199,802
2024-10-28	VKTXViking Therapeutics, Inc.M Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	+4,251 sh	$4.68	+$19.9K	204,053
2024-10-28	VKTXViking Therapeutics, Inc.M Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	+26K sh	$5.80	+$151K	230,053
2024-10-28	VKTXViking Therapeutics, Inc.M Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	+51K sh	$8.52	+$435K	281,053
2024-10-28	VKTXViking Therapeutics, Inc.S Sale	Chief Financial Officer	SSale	−49.7K sh	$74.56	−$3.7M	231,381
2024-10-28	VKTXViking Therapeutics, Inc.S Sale	Chief Financial Officer	SSale	−18.6K sh	$75.79	−$1.41M	212,761
2024-10-28	VKTXViking Therapeutics, Inc.S Sale	Chief Financial Officer	SSale	−9,265 sh	$76.94	−$713K	203,496
2024-10-28	VKTXViking Therapeutics, Inc.S Sale	Chief Financial Officer	SSale	−23.1K sh	$77.68	−$1.79M	180,414
2024-10-28	VKTXViking Therapeutics, Inc.S Sale	Chief Financial Officer	SSale	−15.8K sh	$78.69	−$1.25M	164,589
2024-10-28	VKTXViking Therapeutics, Inc.S Sale	Chief Financial Officer	SSale	−6,050 sh	$79.78	−$483K	158,539
2024-10-28	VKTXViking Therapeutics, Inc.S Sale	Chief Financial Officer	SSale	−7,967 sh	$80.65	−$643K	150,572
2024-10-28	VKTXViking Therapeutics, Inc.S Sale	Chief Financial Officer	SSale	−1,206 sh	$81.44	−$98.2K	149,366
2024-10-28	VKTXViking Therapeutics, Inc. · Stock Option (Right to Buy)M Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	−12.8K sh	—	—	0
2024-10-28	VKTXViking Therapeutics, Inc. · Stock Option (Right to Buy)M Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	−4,251 sh	—	—	0
2024-10-28	VKTXViking Therapeutics, Inc. · Stock Option (Right to Buy)M Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	−26K sh	—	—	0
2024-10-28	VKTXViking Therapeutics, Inc. · Stock Option (Right to Buy)M Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	−51K sh	—	—	153,000
2024-07-30	VKTXViking Therapeutics, Inc.S Sale	Chief Financial Officer	SSale	−12.7K sh	$56.96	−$721K	190,526
2024-07-30	VKTXViking Therapeutics, Inc.S Sale	Chief Financial Officer	SSale	−2,974 sh	$57.71	−$172K	187,552
2024-07-30	VKTXViking Therapeutics, Inc.S Sale	Chief Financial Officer	SSale	−500 sh	$58.71	−$29.4K	187,052
2024-07-29	VKTXViking Therapeutics, Inc.A Award	Chief Financial Officer	AAward	+6,667 sh	—	—	181,521
2024-07-29	VKTXViking Therapeutics, Inc.A Award	Chief Financial Officer	AAward	+21.7K sh	—	—	203,188
2024-05-03	VKTXViking Therapeutics, Inc.M Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	+4,249 sh	$4.68	+$19.9K	211,610
2024-05-03	VKTXViking Therapeutics, Inc.M Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	+30K sh	$4.88	+$146K	241,610
2024-05-03	VKTXViking Therapeutics, Inc.S Sale	Chief Financial Officer	SSale	−3,101 sh	$73.49	−$228K	238,509
2024-05-03	VKTXViking Therapeutics, Inc.S Sale	Chief Financial Officer	SSale	−45.6K sh	$74.44	−$3.39M	192,939
2024-05-03	VKTXViking Therapeutics, Inc.S Sale	Chief Financial Officer	SSale	−17.2K sh	$75.49	−$1.3M	175,701
2024-05-03	VKTXViking Therapeutics, Inc.S Sale	Chief Financial Officer	SSale	−847 sh	$76.07	−$64.4K	174,854
2024-05-03	VKTXViking Therapeutics, Inc. · Stock Option (Right to Buy)M Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	−4,249 sh	—	—	4,251
2024-05-03	VKTXViking Therapeutics, Inc. · Stock Option (Right to Buy)M Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	−30K sh	—	—	60,000
2024-03-27	VKTXViking Therapeutics, Inc.A Award	Chief Financial Officer	AAward	+31.7K sh	—	—	223,971
2024-03-27	VKTXViking Therapeutics, Inc.F Tax Payment	Chief Financial Officer	FTax Payment	−16.6K sh	$83.34	−$1.38M	207,361
2024-03-01	VKTXViking Therapeutics, Inc.A Award	Chief Financial Officer	AAward	+31.7K sh	—	—	212,397

Recent filings

Accepted (ET)
Jul 294
ZANTE GREG0001193125-26-324447
SEC(opens sec.gov)
Jan 54
ZANTE GREG0001193125-26-003116
SEC(opens sec.gov)
Oct 284
ZANTE GREG0001193125-25-254298
SEC(opens sec.gov)
Jul 34
ZANTE GREG0000950170-25-093792
SEC(opens sec.gov)
Jan 64
ZANTE GREG0000950170-25-002485
SEC(opens sec.gov)
Oct 284
ZANTE GREG0000950170-24-117885
SEC(opens sec.gov)

Companies

Address

C/O VIKING THERAPEUTICS, INC. 9920 PACIFIC HEIGHTS BLVD, SUITE 350

SAN DIEGO, CA, 92121